This Week in Psychedelics

Massachusetts could legalize this November; Utah unanimously authorizes pilot program for MDMA treatment; update from atai Life Sciences.

March 29, 2024

This Week...

Utah governor Spencer Cox allowed a bill to become law without his signature that authorizes a pilot program for hospitals to administer psilocybin and MDMA as an alternative treatment option.

The governor said in a letter to legislative leaders that he was letting the psychedelics legislation become enacted despite his reservations due to the “overwhelming support” it received, with both chambers unanimously approving the measure. Here’s more:

atai Life Sciences announced positive initial results from Beckley Psytech’s Phase 2a open label study of BPL-003 in Treatment Resistant Depression (TRD), a condition that affects approximately 100 million people worldwide.

BPL-003 is a novel, synthetic, patent-protected benzoate salt formulation of 5-MeO-DMT that is administered intranasally. Initial results demonstrated that a single 10mg dose of BPL-003 was well-tolerated and resulted in a rapid onset and durable antidepressant effect in patients living with TRD. Check it out:

A Massachusetts joint legislative committee held a hearing to discuss an initiative that would legalize psychedelics. The initiative may appear on the November ballot if lawmakers decline to independently enact it first.

Members of the Special Joint Committee on Initiative Petitions took testimony from subject matter experts, supporters and opponents of the measure, which is being spearheaded by the campaign Massachusetts for Mental Health Options (MMHO).

This hearing comes about three months after Secretary of the Commonwealth William Galvin’s office certified that activists had collected 96,277 valid signatures for the reform measure—about 20,000 more than required to force consideration by the legislature. Here’s more:

Did You Know?

Did you know that humans and other animals produce endogenous psychedelics?  

Some are actually identical or closely related to those produced by fungi and plants. Researchers have actually found endogenous psychedelic production in the human brain and gut – the latter of which occurs with the help of symbiotic gut microbes.  

Even more fascinating is that the similarities between exogenous and endogenous psychedelics and the reasons humans synthesize psychoactive compounds are taking scientists on a trip across millions of years of evolution. In doing so, they are discovering connections that span interkingdom and interspecies boundaries. It’s absolutely fascinating stuff! Check it out: